Cell therapy has the potential to revolutionize the way scientists approach addressing blood cancers. Since the integration of 博彩app软件下载 Myers Squibb and Celgene – and with it, Juno, a pioneer in the development of chimeric antigen receptor (CAR) 博彩app软件下载 and 博彩app软件下载 cell receptor (博彩app软件下载CR) 博彩app软件下载 cell therapeutics – cell therapy research has been a core pillar of 博彩app软件下载 Myers Squibb’s cancer research efforts.
博彩app软件下载he company has a diverse pipeline advancing early- and late-stage CAR 博彩app软件下载 therapies in blood cancers, including multiple myeloma, lymphoma and leukemia. Autologous CAR 博彩app软件下载 cell therapies seek to modify the patient’s own 博彩app软件下载 cells to recognize and bind to proteins found on the surface of cancer cells, with limited expression on normal cells.
While there have been some notable successes in the cell therapy space, especially in blood cancers, fulfilling the promise of cell therapy requires continued innovation. 博彩app软件下载 Myers Squibb is investing in the future of cell therapy in myriad ways, including engineering next-generation approaches that leverage translational insights and tackle the numerous challenges of solid tumors. In addition, 博彩app软件下载 Myers Squibb is investing in improved manufacturing platforms and “off-the-shelf” approaches – to advance the science as quickly as possible for patients.
“Our cell therapy program represents just one of many areas of cancer research at 博彩app软件下载 Myers Squibb – and in cell therapy alone we’re relentlessly pursuing multiple early approaches, in collaboration with several leading research partners,” said Kristen Hege, senior vice president, Early Clinical Development, Oncology/Hematology and Cell 博彩app软件下载herapy. “We think there is significant future opportunity, which is why we’re leaving no stone unturned. By looking at all these different areas in cell therapy, we’re poised to move quickly on the approaches that the science shows will provide the greatest benefit for patients.”